Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilofexor in non-cirrhotic primary sclerosing cholangitis
NCT03890120Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Cilofexor 100 mg with Placebo (2 arms). Primary endpoint: Percentage of Participants With Progression of Liver Fibrosis at 96 weeks. Started Mar 2019; status: terminated.
02
Drugs
cilofexor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03890120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890120.